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Speciﬁc EMF-responsivenessFor many years electromagnetic ﬁelds (EMFs) have been used clinically with various settings as an exogenous
stimulation method to promote fracture healing. However, underlying mechanisms of action and EMF parame-
ters responsible for certain effects remain unclear. Our aim was to investigate the inﬂuence of deﬁned EMFs on
human osteoblasts' and osteoclasts' viability and function. Primaryhuman osteoblasts and osteoclastswere treat-
ed 3 times weekly for 21 days during their maturation process using the Somagen® device (Sachtleben GmbH,
Hamburg, Germany), generating deﬁned extremely low-frequency pulsed electromagnetic ﬁelds (ELF-PEMFs).
Certain ELF-PEMF treatment signiﬁcantly increased the total protein content (up to 66%), mitochondrial activity
(up to 91.1%) and alkaline phosphatase (AP) activity (up to 129.9%) of human osteoblasts during the entire dif-
ferentiation process. Furthermore, ELF-PEMF treatment enhanced formation of mineralizedmatrix (up to 276%).
Interestingly, ELF-PEMF dependent induction of AP activity and matrix mineralization was strongly donor
dependent — only osteoblasts with a poor initial osteoblast function responded to the ELF-PEMF treatment.
As a possible regulatory mechanism, activation of the ERK1/2 signaling pathway was identiﬁed. Maturation of
osteoclasts fromhumanmonocyteswas not affected by the ELF-PEMF treatment. In summary the results indicate
that a speciﬁc ELF-PEMF treatment with the Somagen® device improves viability and maturation of osteoblasts,
while osteoclast viability and maturation was not affected. Hence, ELF-PEMF might represent an interesting
adjunct to conventional therapy supporting bone formation during fracture healing or even for the treatment
of osteoporosis.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Thebiological process of fracturehealing is complex and requires the in-
teraction of many factors. If these mechanisms are inadequate or
interrupted, healing is delayed or impaired. In 1974, Bassett and colleagues
reported for the ﬁrst time that electromagnetic ﬁelds (EMFs) may acceler-
ate and improve bone healing (Bassett et al., 1974a). Since then various
forms of electrical ﬁelds, including invasive direct current as well as non-
invasive combined electromagnetic ﬁelds (EMFs) and pulsed electromag-
netic ﬁelds (PEMFs) have been used as exogenous stimulation methods
to promote bone formation, not only to support fracture healing but also
for treatment of osteoporosis (Grifﬁn et al., 2008).ehnert@gmail.com (S. Ehnert).
. This is an open access article underElectrical Direct Current (DC) stimulators, which deliver the cur-
rent through either implanted or percutaneously applied insulated
electrodes, have the advantage of providing a constant challenge di-
rectly at the fracture site and increased patient compliance. However,
due to the invasive nature, this method may result in higher infection
rates and painful implants (Haddad et al., 2007). Therefore, non-
invasive EMFs and PEMFs became more and more popular. Since the
1980s, the FDA has approved several EMF and PEMF devices. These
have been used to treat delayed and non-union bone fractures (Grifﬁn
et al., 2008), for relieving postsurgical pain and edema (Thomas et al.,
2007), to treat chronic wounds or to facilitate vasodilatation and angio-
genesis (Strauch et al., 2009). The described EMFs range from frequen-
cies of 20 Hz to 200 kHz, resulting in electrical ﬁelds in the tissue of
approximately 1 to 100 mV/cm (Aaron et al., 2004). For PEMFs, the
reported conﬁgurations of the applied magnetic ﬁelds vary in theirthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in magnetic ﬁelds of 10 to 2000 μT and voltage gradients of 1 to
100 mV/cm (Aaron et al., 2004). Hence, a broad range of conﬁgurations
of EMFs and PEMFs has been applied clinically on fresh fractures and
osteotomies, spine fusions, as well as delayed and non-union fractures.
Despite this long history of clinical application the underlying mecha-
nisms of action remain poorly understood. Hence, optimal parameters
for the treatment of fractures have not been established yet.
Aim of the present project was to investigate the inﬂuence of select-
ed extremely low-frequency pulsed electromagnetic ﬁelds (ELF-PEMFs)
on primary human bone cells (osteoblasts and osteoclasts). ELF-PEMFs
were generated with the help of the Somagen® (Sachtleben GmbH,
Hamburg, Germany), a device certiﬁed for medical use according
to European laws (CE 0482, compliant with EN ISO 13485:2012 +
AC:2012). The Somagen® device generates ELF-PEMFs with speciﬁc
magnetic ﬁeld strengths and frequency spectra. For the present study
10 programs with frequencies between 10 and 90.6 Hz were chosen
based on data from literature. There are several reports about the appli-
cation of ELF-PEMFs inducing changes in cellular processes, in various
cell types e.g. stem cells, immune cells, skin cells, tumor cells, tendon
and bone cells (Hong et al., 2014; Seeliger et al., 2014; Tofani et al.,
2001; Zhou et al., 2011, 2014). The observed biological effects include
amongst others cell differentiation, apoptosis, DNA synthesis, calcium
ﬂux, protein expression and phosphorylation, anti-inﬂammatory effects
andhormoneproduction. Focusing on the bone, both in vitro and in vivo
studies, have demonstrated that EMF and PEMF treatment induces the
synthesis of extracellular matrix proteins and growth factors, as well
as initiating signaling cascades involved in proliferation and cell survival
(Zhou et al., 2011, 2014; Ciombor andAaron, 2005; Yumoto et al., 2015).
Therefore, as functional readout total protein content, mitochondrial
activity, alkaline phosphatase (AP) and tartrate resistant acidic phos-
phatase (Trap5B) activity as well as matrix mineralization was assessed
during the 3 weeks of maturation of primary human osteoblasts and
osteoclasts. In order to better understand the regulatory mechanisms,
gene expression changes and activation of mitogen activated protein
kinases (MAPKinases), described to be involved in the osteogenic differ-
entiation process, were examined.
2. Materials and methods
Human recombinant (rh)M-CSF and rhRANKLwere purchased from
Peprotech (Hamburg, Germany); cell culturemedium and supplements
were purchased from PAA (Cölbe, Germany); primary and secondary
antibodies were obtained from Cell Signaling (Beverly, USA); chemicals
were purchased from Sigma (Munich, Germany).
2.1. Ethics statement
All human studies were performed in accordance with the 1964
Declaration of Helsinki. Osteoblasts were isolated from bone tissue of
patients undergoing total hip replacement or high tibial osteotomy, in
accordance to the ethical vote (387/2012BO) of the University Clinic
in Tübingen (Eberhard Karls Universität, Tübingen, Germany) and the
patients' written consent. Bone tissue from (potential) tumor patients
or patients with viral or bacterial infections was excluded from this
study.
2.2. Isolation, expansion and maturation of primary human osteoblasts
Brieﬂy, cancellous bone was removed mechanically from the femur
head and washed 3–5 times with DPBS. After 1 h of collagenase diges-
tion (DPBS, 0.07% Collagenase II — Biochrom AG, Berlin, Germany) at
37 °C, cancellous bone was washed with DPBS and released pre-
osteoblasts were transferred to cell culture ﬂasks in culture medium
(MEM/Ham's F12, 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin,
100 μg/ml streptomycin, 50 μM L-ascorbate-2-phosphate, 50 μMβ-glycerol-phosphate) for expansion. Medium was changed every 4–
5 days. Experiments were performed in passage 3 and 4, when a pure
population of osteoblasts was reached (negative for CD14 and CD45
and positive for CD90 and CD105), as determined by ﬂow cytometry
(Ehnert et al., 2010). In order to favor osteogenic differentiation, cells
were cultured in differentiation medium (MEM/Ham's F12, 1% FCS,
2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin,
200 μM L-ascorbate-2-phosphate, 10 mM β-glycerol-phosphate,
25 mM HEPES, 1.5 mM CaCl2, 100 nM dexamethasone) during the
experiments.
2.3. Generation of human osteoclasts
Brieﬂy, human mononuclear cells were isolated from whole blood
samples by density gradient centrifugation as described (Ehnert et al.,
2011). Then, cells were plated in isolation medium (Alpha MEM, 10%
FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin).
Following overnight adherence, mediumwas changed to dedifferentia-
tion medium (Alpha MEM, 10% FCS, 2 mM L-glutamine, 100 U/ml peni-
cillin, 100 μg/ml streptomycin, 2.5 ng/ml rhM-CSF) for 6 days. Osteoclast
differentiation was induced by differentiation medium (Alpha MEM,
10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomy-
cin, 20 ng/ml rhRANKL) for 21 days (Schmitt et al., 2012).
2.4. Electromagnetic ﬁeld application with the Somagen® device
During the entire differentiation process primary human osteoblasts
were exposed to selected ELF-PEMFs 3 times per week (Monday,
Wednesday and Friday) for 7 min. The ELF-PEMFs were generated by
the Somagen® device (Sachtleben GmbH, Hamburg, Germany) and
emitted via two identical applicators located in a positioning board
to ensure precise orientation of the culture dish/multi-well plate
(Fig. 1A). In the present project 10 speciﬁc CIT programs (labeled CIT
program #4, #10, #16, etc.) were selected each a combination of ELF-
PEMF parameters such as fundamental frequency ( = pulse repetition
rate), waveform (spike pulses), intensity (expressed as pulse amplitude
and the corresponding RMS value) and send–pause intervals. The ap-
plied ELF-PEMF frequencies ranged from 10 to 90.6 Hz. For IP reasons
more detailed data will not be published here. The ELF-PEMF applica-
tions were controlled via chip cards and started by simply pushing a
button (Fig. 1B). Fig. 1C gives a simpliﬁed pattern of the magnetic ﬁeld
lines emitted by the applicator (magnetic dipole ﬁeld).
2.5. Sulforhodamine B (SRB) staining for total protein content
SRB staining on ethanol ﬁxed cells was performed as reported
(Skehan et al., 1990) in order to assess the total protein content. Re-
solved stain was quantiﬁed photometrically (λ= 565 nm–690 nm).
2.6. Resazurin conversion assay
Mitochondrial activity (viability) was measured by Resazurin con-
version. Brieﬂy, 1/10 volume of a 0.025% (w/v) Resazurin solution
(inDPBS)was added to the cells. After 1 h of incubation at 37 °C,ﬂuores-
cence intensity was measured (ex/em= 540/590 nm) and corrected to
background control (solvent mixture without cells).
2.7. AP activity measurement
For assessing the AP activity primary human osteoblasts were
incubated with reaction buffer (0.2% 4-nitrophenyl-phosphate, 50 mM
glycine, 1 mM MgCl2, 100 mM TRIS, pH 10.5) at 37 °C. Resulting for-
mation of 4-nitrophenol (yellow) was determined photometrically
(λ = 405 nm). Signals were normalized to relative cell numbers by
Resazurin conversion (Ehnert et al., 2010).
Fig. 1. Representation of the Somagen® device used to generate electromagnetic ﬁelds. (A) Primary human osteoblasts were exposed to ELF-PEMFs generated by the Somagen® device
(Sachtleben GmbH, Hamburg, Germany). ELF-PEMF emission via two identical applicators located in a positioning board to ensure precise orientation of a culture dish/multi-well
plate. (B) Control of speciﬁc ELF-PEMF parameters via chip cards, user-friendly by simply pushing the start button. (C) Simpliﬁed pattern of magnetic ﬁeld lines emitted by the applicator
(magnetic dipole ﬁeld).
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Brieﬂy, ethanol ﬁxed primary human osteoblasts were washed 3
times with tap water, then incubated with the corresponding staining
solutions: (i) for von Kossa staining 3% silver-nitrate solution for
30 min at ambient temperature, followed by 3 additional washing
steps and incubation with sodium-carbonate-formaldehyde solution
(0.5 M sodium-carbonate, 10% formaldehyde) for color development
(brownish-black). The staining was quantiﬁed by densitometric analy-
sis using the ImageJ software (NIH, Bethesda, USA); (ii) for Alizarin
Red staining 0.5% Alizarin Red solution (pH 4.0) for 30 min at ambient
temperature. After 3 additional washing steps, Alizarin Red staining
was resolved with 10% Cetylpyridiumchloride solution and quantiﬁed
photometrically (λ= 562 nm) (Ehnert et al., 2010).2.9. Semi-quantitative RT-PCR
Total cellular RNA was isolated using Trifast (Peqlab, Erlangen,
Germany) according to the manufacturer's protocol. First-strand cDNA
was synthesized from 2 μg of total RNA using the First Strand cDNA Syn-
thesis Kit from Fermentas (St. Leon-Rot, Germany). Primer sequences
and PCR conditions were as published (Ehnert et al., 2015; Freude
et al., 2012). Products, separated by gel electrophoresis in a 1.8% (w/v)
agarose gel, were visualized with ethidium bromide. Densitometric
analysis of signals was performed using the ImageJ software (NIH,
Bethesda, USA).2.10. Western blot
Cells were lyzed in freshly prepared ice-cold RIPA buffer (50 mM
TRIS, 250 mM NaCl, 2% Nonidet-P40, 2.5 mM EDTA, 0.1% SDS, 0.5%
DOC, protease and phosphatase inhibitors, pH 7.2). Protein concentra-
tion was determined by micro-Lowry (Lowry et al., 1951). 30 μg of
total proteinwere separated by SDS-PAGE and transferred to nitrocellu-
lose membranes (Roth, Karlsruhe, Germany). Unspeciﬁc binding sites
were blocked with 5% BSA in TBST solution (25 mM Tris, 137 mM
NaCl, 2.7mMKCl, 0.05% Tween-20, pH 7.4) for 1 h at RT. After overnight
incubation with primary antibodies (Cell Signaling, Beverly, USA) dilut-
ed 1:1000 in TBST at 4 °C, membranes were incubated with the corre-
sponding HRP-labeled secondary antibodies (1:10,000 in TBST) for 2 h
at RT. For signal development, membranes were incubated for 1 min
with ECL substrate solution (1.25 mM luminol, 0.2 mM p-coumaric
acid, 0.03% H2O2 in 100 mM TRIS, pH 8.5). Chemiluminescent signals
were detected with a CCD camera. Signal intensities were determined
by densitometry using the ImageJ software (NIH, Bethesda, USA) and
normalized to the corresponding GAPDH signals (Wang et al., 2014).2.11. Trap5B activity assay and staining
Trap5B activity was measured in culture supernatants. 30 μl of
culture supernatant was mixed with 90 μl of Trap5B activity assay
buffer (0.2% 4-nitrophenyl-phosphate, 100 mM Na-acetate, 50 mM
Na2-tartrate, pH 5.5) and incubated for 1 h at 37 °C. Reaction was
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nitrophenol (yellow) was determined photometrically (λ =
405 nm). Signals were normalized to relative cell numbers by
Resazurin conversion. Trap5B staining was performed as described
(Schmitt et al., 2012).
2.12. Statistics
Results are expressed as mean or median ± SEM of at least 5 inde-
pendent experiments (N ≥ 5) measured as triplicates or quadruplicates
(n = 3 or 4). Details are given in the ﬁgure legends. Data sets with two
groups were compared by Wilcoxon matched pairs test. Data sets with
more than two groups were compared by non-parametric one-way
analysis of variance (Kruskal Wallis) followed by Dunn's multiple com-
parison test (GraphPad Prism Software, El Camino Real, USA). p b 0.05
was taken as minimum level of signiﬁcance.
3. Results
3.1. ELF-PEMF application improves viability and maturation of primary
human osteoblasts
Using the Somagen® device primary human osteoblasts (N = 12)
were exposed to 10 selected ELF-PEMFs 3 times per week (Monday,
Wednesday and Friday) over the course of 21 days. Total protein
content,mitochondrial activity (viability), AP activity andmatrixminer-
alization were determined on day 0, 7, 14, and 21 of culture (Fig. 2A–E).
In order to better reﬂect changes of different functions over the entire
differentiation process, the area under the curve (AUC) was determined
(Fig. 2F).
Throughout the entire maturation process total protein content and
viability (mitochondrial activity) of primary human osteoblasts were
increased by the ELF-PEMF application. On average the total protein
content increased by+49.7% (+34% to+66%) over the entire duration
of the experiment determined by the relative increase of the area under
the curve (AUC). The highest protein content (+66% increase as com-
pared to untreated cells) was observed in primary human osteoblasts
exposed to ELF-PEMF CIT #81 (Fig. 2A & F). Similar to the total protein
content the viability (mitochondrial activity) increased. The highest
mitochondrial activity (+91.1% increase as compared to untreated
cells) was measured in primary human osteoblasts exposed to ELF-
PEMF CIT #64 (Fig. 2B & F).
On average AP activity was induced by ELF-PEMF treatment over the
entire maturation process. The strongest induction of AP activity
in primary human osteoblasts was observed in cells exposed to ELF-
PEMF CIT #16 and #20 (+127.4% and +129.9% increase as compared
to untreated cells/Fig. 2C & F). As the strongest differences were
observed early in the differentiation process, ELF-PEMF effects on AP
activity were determined on day 7 in subsequent experiments. Similar
to the AP activity also matrix mineralization was induced by ELF-PEMF
treatment, as determined by von Kossa and Alizarin Red staining. Stron-
gest induction ofmatrixmineralizationwas observed in primary human
osteoblasts exposed to ELF-PEMF CIT #16 (+276% increase as com-
pared to untreated cells/Fig. 2D–F).
Taken into account the effects for both viability and functionality
ELF-PEMF CIT #16 treatment showed the strongest effects. These results
led to the application of ELF-PEMF CIT #16 for all subsequent experi-
ments (Fig. 2F). If not otherwise stated, subsequently the term ELF-
PEMF refers to this speciﬁc CIT program.
3.2. Human osteoblasts with low initial AP activity respond well to the
ELF-PEMF treatment
However, the observed induction of AP activity and matrix mineral-
ization was strongly donor-dependent. While some donors responded
strongly to the ELF-PEMF treatment, other donors were not affectedat all. Donors with a high initial (day 0) AP activity formed lots of min-
eralized matrix, which could not be further improved by the ELF-PEMF
treatment. Thus, these donors (N= 9)were deﬁned as “ELF-PEMF non-
responsive”. On the other hand, donors with low initial (day 0) AP
activity and resulting deﬁcits in matrix mineralization responded to
treatment with the ELF-PEMF. Thus, these donors (N = 28) were
termed “ELF-PEMF responsive” (Fig. 3A).
Considering these two groups, the initial (day 0) total protein con-
tent was slightly lower in ELF-PEMF responsive cells as compared to
ELF-PEMF non-responsive cells. In these ELF-PEMF responsive cells the
total protein contentwas increased by 46.3% (as compared to untreated
cells) upon exposure to the ELF-PEMF (CIT #16/day 7), reaching total
protein levels comparable to ELF-PEMF non-responsive cells (Fig. 3B).
The basal mitochondrial activity (viability/day 0) was comparable
between both responder groups. Furthermore, mitochondrial activity
was comparably induced by ELF-PEMF treatment (data not shown).
Differences in the functional parameter AP activity and matrix min-
eralization between the two responder groups were more pronounced.
On day 0, the AP activity in ELF-PEMF responsive osteoblasts measured
about 1/3 of the AP activity in ELF-PEMF non-responsive osteoblasts.
Within 7 days of differentiation the AP activity increased approximately
2 fold in both the responder and non-responder group. In the non-
responder group AP activity of cells could not be further increased by
ELF-PEMF (CIT #16). In the ELF-PEMF responsive cells the AP activity
was further increased by 62.5% by CIT #16, reaching almost the level
of the ELF-PEMF non-responsive osteoblasts (Fig. 3C). Similar to AP
activity matrix mineralization was found to be signiﬁcantly lower
in ELF-PEMF responsive osteoblasts. While in the ELF-PEMF non-
responsive osteoblasts matrix mineralization could not be further in-
creased by ELF-PEMF exposure, ELF-PEMF responsive osteoblasts
produced signiﬁcantly more mineralized matrix when exposed to
CIT #16 (Fig. 3D).
3.3. ELF-PEMF application alters the expression of osteogenic transcription
factors
Subsequently the effect of ELF-PEMF (CIT #16) on the expression of
osteogenic transcription factors Runx2, SP7 (osterix), ATF4, STAT1 and
Satb2 was investigated by semiquantitative RT-PCR in ELF-PEMF
responsive osteoblasts. For this purpose primary human osteoblasts
were differentiated in the presence or absence of ELF-PEMF (CIT #16)
for 7 and 21 days (N = 5, n = 4 respectively). Expression of the early
osteogenic transcription factor Runx2 was not affected after 7 days of
differentiation, but expression of the late osteogenic transcription factor
SP7 (osterix) was signiﬁcantly induced (approx. +250%). At this time
point expression of the regulatory transcription factors ATF4, STAT1
and Satb2were not signiﬁcantly affected, but Satb2 showed an increas-
ing trend. Interestingly, after 21 days of differentiation a signiﬁcant
down-regulation of Runx2 and its regulators ATF4, STAT1, and Satb2
were detected in the ELF-PEMF (CIT #16) exposed cells compared to
untreated controls (Fig. 4A & B).
3.4. ERK1/2 activation is pivotal for improving the osteogenic function by
ELF-PEMF exposure with the Somagen® device
In order to elucidate possible underlying molecular mechanisms
of action activated by ELF-PEMF, the following experiments were
performed with primary human osteoblasts exhibiting a low initial AP
activity (N = 5/ELF-PEMF responsive). 15, 30, 60 and 120 min after
exposure to CIT #16 activation/phosphorylation of signaling molecules
(HSP27, p38, AKT, ERK1/2, JNK and 90RSK) were investigated
(Fig. 5A). Activation of JNK could not be detected (data not shown).
Densitometric analysis (n = 4) of the Western blot signals revealed
a continuous but not signiﬁcant increase of phospho-HSP27 and
phospho-AKT in primary human osteoblasts exposed to ELF-PEMF CIT
#16. Phospho-p38 was slightly increased due to ELF-PEMF exposure,
Fig. 2. ELF-PEMF application with the Somagen® device improved viability and function of primary human osteoblasts. Primary human osteoblasts (N= 12, n = 4) were exposed to 10
speciﬁc ELF-PEMFs 3 times perweek (Monday,Wednesday and Friday), for 7min each day. ELF-PEMFswith 10 speciﬁc frequencieswere generated using the Somagen® device. On day 0,
7, 14 and 21 of culture (A) total protein content was determined by SRB staining, (B) mitochondrial activity (viability) was determined by Resazurin conversion, (C) AP activity was
determined by pNPP conversion and matrix mineralization was determined by (D) Alizarin Red and (E) von Kossa staining. In the graphs data are represented as median ± SEM. The
red curve represents untreated cells (Ø). The green curve marks the program with the strongest effect over the entire observation period. (F) To evaluate the ELF-PEMF effect over the
entire culture period the area under the curve (AUC) was determined. %—changes were calculated based on the AUC.
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also showed an increasing trend following ELF-PEMF exposure with
a signal peak at 30 min. A similar pattern was observed for its up-
stream signaling partner phospho-ERK1/2 which was signiﬁcantly(approx. +600%) increased upon ELF-PEMF CIT #16 exposure
(Fig. 5B).
As p38 and ERK1/2 signaling was signiﬁcantly activated by ELF-
PEMF CIT #16 exposure, their effect on the osteogenic function after
Fig. 3. Primary human osteoblasts with low initial AP activity respondwell to the ELF-PEMF CIT #16 exposure. (A) Correlation between initial AP activity (day 0) andmatrixmineralization
after 21 days in untreated cells (N= 37). Cells with a high initial AP activity (N= 9, n= 4) produced huge amounts of mineralizedmatrix. The function of these cells could not be further
improvedby ELF-PEMFCIT #16 exposure (ELF-PEMFnon-responsive cells/light bars). Cellswith a low initial AP activity (N=28, n=4)produced littlemineralizedmatrix. The function of
these cells could be signiﬁcantly improved by ELF-PEMF CIT #16 exposure (ELF-PEMF responsive cells/dark bars). To further distinguish between the two responder groups primary
human osteoblasts were exposed to ELF-PEMF CIT #16, generated with the Somagen® device, 3 times per week (Monday, Wednesday and Friday), for 7 min each day (hatched bars).
After 0 and 7 days (B) total protein content/SRB staining and (C) AP activity were determined. (D) On day 0, 14 and 21 matrix mineralization was quantiﬁed by Alizarin Red staining.
Data are calculated relative to the average of all cells on day 0 and displayed as mean ± SEM. * p b 0.05, ** p b 0.01 *** p b 0.001 as indicated.
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by the chemical inhibitor SB203580 did not show an inﬂuence
on the AP activity or matrix mineralization. However, inhibitionFig. 4. ELF-PEMF CIT #16 application induces the expression of the late osteogenic transcription
Runx2, SP7 (osterix), ATF4, STAT1 and Satb2 for primary human osteoblasts (ELF-PEMF-respon
GAPDH was used as house-keeping gene. (B) Densitometric analysis (N = 5, n = 4) of the RT
in relative gene expression as compared to untreated cells. * p b 0.05, ** p b 0.01 *** p b 0.001of the ERK1/2 signal transduction with inhibitor U0126 signiﬁ-
cantly reduced both AP activity as well as matrix mineralization
(Fig. 5C & D).factor SP7 (osterix) in primary human osteoblasts. (A) Representative RT-PCR picture for
sive) after 7 and 21 days of differentiation with or without ELF-PEMF CIT #16 exposure.
-PCR signals was performed using the ImageJ software. Data are represented as %-change
as compared to untreated cells.
Fig. 5. Regulation of MAPKinases by ELF-PEMF CIT #16. (A) Representative Western blot for phospho-HSP27, phospho-p38, phospho-AKT, phospho-ERK1/2 and phospho-90RSK in
primary human osteoblasts (ELF-PEMF-responsive) 15, 30, 60, 120 min after exposure to the ELF-PEMF CIT #16 using the Somagen® device. GAPDH was used as loading control.
(B) Densitometric analysis (N = 5, n = 4) of the Western blot signals was performed using the ImageJ Software. Intensities are given as %-change of untreated cells. To investigate the
role of the MAPKinase activation in ELF-PEMF induced osteoblast function, primary human osteoblasts were differentiated with and without exposure to the ELF-PEMF CIT #16 in the
presence and absence of chemical inhibitors for p38 (SB203580) and ERK1/2 (U0126) signaling. (C) After 7 days AP activity was measured and (D) after 21 days matrix mineralization
was quantiﬁed by Alizarin Red staining. All data were normalized to untreated cells. * p b 0.05, ** p b 0.01 *** p b 0.001 as compared to untreated cells.
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osteoclasts
After observing the positive effects of ELF-PEMF CIT #16 on osteo-
blast viability and function, we sought to further investigate the effect
of this ELF-PEMF on human osteoclasts. Hence, we generated osteo-
clasts from peripheral bloodmonocytes (N=4). During the 3week dif-
ferentiation process, the cells were exposed to the ELF-PEMF CIT #16 3
times per week (Monday, Wednesday and Friday). After 21 days of
differentiation, cell viability (mitochondrial activity), Trap5B staining
and activity were determined. No signiﬁcant differences for viability
or Trap5B activity were observed between ELF-PEMF treated and
untreated cells (Fig. 6A–C).
4. Discussion
In the early 1970s, Bassett and colleagues reported for the ﬁrst time
that electromagnetic ﬁelds may accelerate and improve bone healing
(Bassett et al., 1974b). Since then, the FDA has approved several EMF
and PEMF devices. These devices have been used clinically as exogenous
stimulation methods to promote bone formation, for many years
(Grifﬁn et al., 2008). Although positive effects of EMFs and PEMFs onosteotomies, spine fusions, as well as delayed and non-union fractures
are documented, little is known about the underlying mechanisms of
action. In vivo, electrical and electromagnetic ﬁelds are assumed to
play a role in bone healing through the same principles as mechanical
stress applications. When mechanical load is applied to bone, a strain
gradient develops. Subsequent pressure gradients in the interstitial
ﬂuid cause ﬂow-related shear stress and electrical potentials subse-
quent to the compensating ﬂuid streaming (Hannouche et al., 2001).
However, the underlying molecular mechanisms are not explained
as easily. Several theories are favored within the bioelectromagnetic
society, e.g. the molecular gyroscope model (Binhi and Savin, 2002),
Lorentz models (Muehsam and Pilla, 2009a,b), DNA antenna model
(Blank and Goodman, 2011), radical pair model (Foley et al., 2011),
and ion cyclotron resonance (Bawin et al., 1975). It might well be that
effects triggered by the ELF-PEMFs described here can be explained by
a combination of these theories.
In the present project, we investigated the effect of ELF-PEMFs on
the viability and function of primary human osteoblasts and osteoclasts.
ELF-PEMFs were generated with the Somagen® device which is certi-
ﬁed for medical use according to European laws. In the ﬁrst project
phase 10 ELF-PEMF programs with frequencies ranging between
10 Hz and 90.6 Hz were applied in order to identify the most potent
Fig. 6. Osteoclast differentiation was not affected by ELF-PEMF CIT #16. To investigate the effect of ELF-PEMF CIT #16 on osteoclast maturation and function, we differentiated peripheral
bloodmonocytes (N=4, n=4) to osteoclasts in the presence or absence of the CIT Technology. After 3weeks of differentiation, no signiﬁcant difference in (A) themitochondrial activity/
resazurin conversion, (B) the Trap5b staining (100× and 200× magniﬁcation) and (C) the Trap5b activity was observed.
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identiﬁed ELF-PEMF CIT #16 in order to identify possible regulatory
mechanisms.
Focusing on the bone there are both in vitro and in vivo studies
suggesting that EMFs and PEMFsmight induce protein synthesis and ac-
tivate signaling cascades involved in proliferation and cell survival using
such devices (Aaron et al., 2004; Zhou et al., 2014; Ciombor and Aaron,
2005; Hannouche et al., 2001). In our experiments, the ELF-PEMF treat-
ment induced protein synthesis and mitochondrial activity of primary
human osteoblasts, suggesting a slight induction of proliferation in
EMF-PEMF exposed cells. This is in clear contrast to the observations
of Zhou et al., who investigated different EMF waveforms showing
an inhibition of proliferation in rat osteoblasts exposed to sinusoidal
EMFs (50 Hz/0.9–4.8 mT) (Zhou et al., 2011, 2014). In this study the ef-
fects on viability/proliferation seem to be independent of the applied
frequency. This is in linewith the series of preclinical and clinical studies
on electrical and electromagnetic energy on bones that Aaron et al.
reviewed (Aaron et al., 2004). Most frequently, the application of
PEMF and their role on regulation of structural extra-cellular matrix
proteins have been explored. Ciombor and colleagues suggest that the
application of electromagnetic ﬁelds, both in vitro and in vivo, stimulate
the synthesis of structural proteins of the extracellular matrix (Ciombor
andAaron, 2005). Production of extracellularmatrix, however, is amea-
sure of the differentiation potential of osteoblasts.
Contrary to general stimulation of protein synthesis and mitochon-
drial activity, in our experiments the ELF-PEMF mediated modulation
of differentiation potential of osteoblasts was strongly donor depen-
dent. The strongest induction of AP activity and matrix mineralization
(von Kossa and Alizarin Red staining) was observed in primary human
osteoblasts exposed to two speciﬁc ELF-PEMFs (CIT programs #16 and
#10).
Expression of many of thematrix proteins, e.g. collagen type I, ﬁbro-
nectin or osteocalcin, as well as the following matrix mineralization
are controlled by a deﬁned interplay between the key osteogenic tran-
scription factors RUNX2, ATF4, SATB2, STAT1 and osterix (SP7) (Ducy
et al., 1997). Using the Somagen® device, we observed an early up-
regulation of osterix (SP7), ATF, and SATB2. SATB2 is an adapter mole-
cule between ATF4 and RUNX2, increasing their activity (Dobreva
et al., 2006). Osterix (SP7) acts downstream of RUNX2 and is mainly
expressed during late osteogenesis (Nakashima et al., 2002). This points
towards an accelerated osteogenic maturation caused by the ELF-PEMF
(CIT #16). Contrary to ATF4 and SATB2, STAT1 inhibits the activity of
RUNX2 by inducing conformational changes in the nuclear localization
sequence of this transcription factor. Thus, STAT1 knock-out mice
display a predominant increase in osteoblast differentiation leading toa signiﬁcantly higher bonemineral density (Kim et al., 2003). In the pri-
mary human osteoblasts treated with the CIT Technology, we observed
an early down-regulation of STAT1 gene expression. Our results are in
line with several studies showing increased expression of transcription
factors and growth factors, which enhance cellular repair and the
synthesis of extra-cellular matrix proteins (Hannouche et al., 2001),
which might explain the observed increase in AP activity and matrix
mineralization. This result is supported by the work of Zhang and col-
leagues who showed an increased calcium up-take in osteoblasts treat-
ed with ELF-PEMF in the range of 50 Hz and 0.8mT (Zhang et al., 2010).
Also Zhou et al., showed an improved AP activity andmatrixmineraliza-
tion evoked in rat calvarial osteoblasts by sinusoidal EMFs (50 Hz) with
an intensity of 1.8 mT and 3.6 mT (Zhou et al., 2014).
It has been suggested that the application of electromagnetic ﬁelds
may activate transmembrane receptors, e.g. parathyroid hormone, insu-
lin, transferrin or calcitonin receptors, thus initiating signaling cascades
(Ciombor and Aaron, 2005). In our experiments, we observed a strong
activation of the ERK1/2 signaling pathway in primary human osteo-
blasts after ELF-PEMF (CIT #16) treatment. Inhibition of ERK1/2 signal-
ing with the inhibitor U0126 prevented activation of AP activity and
matrix mineralization by ELF-PEMF (CIT #16) treatment, leading to
the conclusion that activation of the ERK1/2 signaling cascade is pivotal
for the observed positive effects of this ELF-PEMF treatment on osteo-
blast function. Our result is supported by the work of Goodman and
colleagues showing an ELF-PEMF-dependent activation of the ERK1/2
signaling cascade in planaria, which is correlated to an increased regen-
eration rate (Goodman et al., 2009). Also Yumoto and colleagues found
in mouse calvaria cell line MC3T3-E1 that electromagnetic wave irradi-
ation increases osteoblastic cell activity and the expression of growth
factors via ERK1/2 and p38 MAPK pathways (Yumoto et al., 2015).
Taken together these observations from planaria, rodents and human
leads to the assumption that EMF mediated ERK1/2 activation is a gen-
eral principle. A possible mechanistic explanation to this phenomenon
is given by Friedman et. al linking ERK1/2 activation to radical pair
mechanism mediated through plasma membrane by NADH oxidase
generating ROS (Friedman et al., 2007).
Considering proliferation and differentiation of osteoblasts as equal-
ly important for a future clinical application to support bone formation,
ELF-PEMF exposure with the Somagen® device applying CIT #16
showed the strongest effects on primary human osteoblasts over the
entire observation period. However, in our study only osteoblasts
from donors with an initially low AP activity and consequently little
matrix mineralization capacity were sensitive towards the ELF-PEMF
treatment. These results indicate a possible clinical use of the Somagen®
device applying ELF-PEMF CIT #16 for fracture healing or treatment of
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matrix mineralization after the differentiation process, was also de-
scribed in jaw periosteal cells (Alexander et al., 2010). Thus, circulating
bone-speciﬁc AP levels might be used as a possible predictivemarker to
identify patients' responsiveness to the ELF-PEMF treatment.
Hong and co-workers (Hong et al., 2014) could show that EMF
controlled osteoclast activity can be inversely correlated to the osteo-
blasts activity. Also Rubin and colleagues suggest that osteoclast for-
mation might be suppressed by low frequency, low intensity electric
ﬁelds (Rubin et al., 1996). Interestingly, ELF-PEMF exposure with the
Somagen®device (CIT#16) did not signiﬁcantly affect osteoclast viabil-
ity or function in our hands.
5. Conclusion
Summarizing our results, speciﬁc ELF-PEMF treatment with the
Somagen® device (CIT #16) improves the viability/proliferation
and accelerates the osteogenic differentiation of primary human
osteoblasts. Strikingly, only osteoblasts with an initial low AP activity
and consequently little matrix mineralization after differentiation were
responsive to the ELF-PEMF treatment. Seeing also that osteoclast mat-
uration was not affected by ELF-PEMF CIT #16 this technology might
present an interesting adjunct to conventional therapy supporting
bone formation during fracture healing or even during the treatment
of osteoporosis.
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